Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1065-1076

  Peters, Bas J M ^a   Rodin, Andrei S ^b   Klungel, Olaf H ^a   Van Duijn, Cornelia M ^c   Stricker, Bruno H Ch ^c   Slot, Ruben Vant ^d   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ABCB1; case control study; drug transporter; myocardial infarction; pharmacogenetics; pharmacogenomics; SLCO1B1; statins

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; ORAL ANTIDIABETIC AGENT; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME SPECIFICITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PHARMACOGENETICS; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; FEMALE; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICAL RECORDS; MIDDLE AGED; MYOCARDIAL INFARCTION; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 77955631252     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.81     Document Type: Article

References (40)

1. Peters BJ, Klungel OH, de Boer A, Maitland-van der Zee AH: Genetic determinants of response to statins. Expert Rev. Cardiovasc. Ther. 7(8), 977-983 (2009).
2. Couvert P, Giral P, Dejager S et al.: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fuvastatin therapy. Pharmacogenomics 9(9), 1217-1227 (2008).
3. Fiegenbaum M, da Silveira FR, van der Sand CR et al.: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering effcacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78(5), 551-558 (2005).
4. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: Polymorphisms in the multidrug resistance-1 (MDR1) gene infuence the response to atorvastatin treatment in a gender-specifc manner. Am. J. Cardiol. 93(8), 1046-1050 (2004).
5. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M: ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin. Pharmacol. Ther. 84(4), 457-461 (2008).
6. Link E, Parish S, Armitage J et al.; SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
7. Maeda K, Ieiri I, Yasuda K et al.: Effects of organic anion transporting polypeptide 1B1 haplotype on harmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79(5), 427-439 (2006).
8. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75(5), 415-421 (2004).
9. Niemi M: Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8(7), 787-802 (2007).
10. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fuvastatin. Clin. Pharmacol. Ther. 80(4), 356-366 (2006).
11. Tachibana-Iimori R, Tabara Y, Kusuhara H et al.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19(5), 375-380 (2004).
12. Thompson JF, Man M, Johnson KJ et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5(6), 352-358 (2005).
13. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics 10(11), 1743-1751 (2009).
14. Hagenbuch B, Meier PJ: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609(1), 1-18 (2003).
15. Cascorbi I: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112(2), 457-473 (2006).
16. Chen C, Mireles RJ, Campbell SD et al.: Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33(4), 537-546 (2005).
17. Voora D, Shah SH, Spasojevic I et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609-1616 (2009).
18. Mangravite LM, Krauss RM: Pharmacogenomics of statin response. Curr. Opin. Lipidol. 18(4), 409-414 (2007).
19. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6(6), 360-374 (2006).
20. Herings RM, Bakker A, Stricker BH, Nap G: Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J. Epidemiol. Community Health 46(2), 136-140 (1992).
21. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A et al.: Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm. World Sci. 31(2), 158-164 (2009).
22. Frazer KA, Ballinger DG, Cox DR et al.; International HapMap Consortium: A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
23. Lao O, Lu T T, Nothnagel M et al.: Correlation between genetic and geographic structure in Europe. Curr. Biol. 18(16), 1241-1248 (2008).
24. Grover D, Woodfeld AS, Verma R, Zandi PP, Levinson DF, Potash JB: QuickSNP: an automated web server for selection of tagSNPs. Nucleic Acids Res. 35(Web Server issue), W115-W120 (2007).
25. Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003).
26. Kim RB, Leake BF, Choo EF et al.: Identifcation of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
27. Khoury MJ, Flanders WD: Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am. J. Epidemiol. 144(3), 207-213 (1996).
28. Storey JD, Tibshirani R: Statistical signifcance for genomewide studies. Proc. Natl Acad. Sci. USA 100(16), 9440-9445 (2003).
29. Aarnoudse AJ, Dieleman JP, Visser LE et al.: Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet. Genomics 18(4), 299-305 (2008).
30. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
31. Neuvonen PJ, Backman JT, Niemi M: Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fuvastatin and pravastatin. Clin. Pharmacokinet. 47(7), 463-474 (2008).
32. Arnaud C, Braunersreuther V, Mach F: Toward immunomodulatory and anti-infammatory properties of statins. Trends Cardiovasc. Med. 15(6), 202-206 (2005).
33. Glynn RJ, Danielson E, Fonseca FA et al.: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360(18), 1851-1861 (2009).
34. Jeannesson E, Siest G, Bastien B et al.: Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clin. Chim. Acta 403(1-2), 198-202 (2009).
35. Cheung BM, Lauder IJ, Lau CP, Kumana CR: Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. 57(5), 640-651 (2004).
36. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD: Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch. Intern. Med. 169(3), 260-268 (2009).
37. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82(6), 726-733 (2007).
38. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873-879 (2006).
39. Lau HS, de Boer A, Beuning KS, Porsius A: Validation of pharmacy records in drug exposure assessment. J. Clin. Epidemiol. 50(5), 619-625 (1997).
40. Smith NL, Hindorff LA, Heckbert SR et al.: Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 297(5), 489-498 (2007).